Literature DB >> 19561898

Isoniazid- and ethambutol-induced psychosis.

R Prasad1, Rajiv Garg, Sanjay Kumar Verma.   

Abstract

Most cases of antituberculous agent-associated psychoses were caused by isoniazid (INH), with ethambutol (EMB)-induced psychosis being rare. The concomitant occurrence of INH- and EMB- induced psychosis and in a single individual is extremely uncommon. We report a case of 28-year-old male who developed psychotic symptoms on start of EMB initially and later on INH also. He was prescribed rifampicin, pyrazinamide, and ofloxacin and had no further psychotic symptoms.

Entities:  

Keywords:  Ethambutol; isoniazid; psychosis

Year:  2008        PMID: 19561898      PMCID: PMC2700450          DOI: 10.4103/1817-1737.43083

Source DB:  PubMed          Journal:  Ann Thorac Med        ISSN: 1998-3557            Impact factor:   2.219


Isoniazid (INH) is included in all drug regimens used for the treatment of tuberculosis because of its potency, safety and low cost. The most common adverse reactions observed with INH are peripheral neuropathy and hepatitis. In our review of the literature, we found that most cases of antituberculous agent–associated psychoses were caused by INH, with ethambutol (EMB)-induced psychosis being rare. The concomitant occurrence of INH- and EMB-induced psychosis and in a single individual, an extremely uncommon event, prompted us to report this case.

Case Report

A 28-year-old male, a nonsmoker, was admitted to our department with the complaints of recurrent hemoptysis and loss of appetite for 1 month. His past history was not significant. His resting pulse rate was 102/min and blood pressure was 112/74 mm Hg and his respiratory rate was 26/min. His general examination revealed no significant abnormality. His respiratory system examination revealed bilateral coarse crepitations. He was given symptomatic treatment for the hemoptysis and a chest x-ray was taken, which showed infiltrative lesions confined to the upper zones of both lungs. His blood examination revealed a total leucocyte count of 10,200/cmm; the differential count showed 66% polymorphs and 34% lymphocytes. His PPD showed 30 mm induration. Sputum tested on three consecutive days was positive for AFB. He was prescribed short-course antituberculous treatment as per WHO guidelines, with an initial 2 months of rifampicin, isoniazid, ethambutol, and pyrazinamide followed by 4 months of rifampicin and isoniazid. The first 3 days of treatment with this four-drug regimen was uneventful. On the fourth day, however, the patient suddenly became restless, irritable, and agitated, with aimless, incongruous acts, and irrelevant talking; he also started having visual hallucinations. He had no past history of any mental illness. There was no neurological deficit and fundus examination was normal (as per the neurology evaluation). An initial diagnosis of drug-induced psychosis was made after a psychiatric consultation, with isoniazid being identified as the likely culprit. The patient's symptoms responded to an injection of diazepam. All the antituberculous drugs were withdrawn. The patient became free of psychotic symptoms over the next 2 days. Antituberculous therapy was now restarted, with ethambutol, rifampicin, and pyrazinamide being added one by one, starting with a low ‘test’ dose of each [Table 1]. We avoided isoniazid initially since we were fairly certain that it was the offending agent. As can be seen from the table, psychotic symptoms were seen 5 days after ethambutol was started, disappeared after the drug was stopped, and recurred when it was restarted. Similarly, we were able to show that isoniazid could also independently bring on the symptoms and that withdrawal of the drug led to remission of symptoms.
Table 1

The reintroduction schedule of antituberculous drugs in present case report

DaysDrug givenAppearance of psychotic symptoms
Day 1Ethambutol 300 mgNo
Day 2Ethambutol 600 mgNo
Day 3Ethambutol 800 mgNo
Day 4Rifampicin 150 mg + ethambutol 800 mgNo
Day 5Rifampicin 300 mg + ethambutol 800 mgAppearance of psychotic symptoms
Day 6All drugs stoppedPsychotic symptoms persisted
Day 7All drugs stoppedPsychotic symptoms resolved
Day 8Ethambutol 300 mgNo
Day 9Ethambutol 600 mg
Thus, the ethambutol could be proved to be the responsible for the causation of the psychotic symptoms and could not be reintroduced.Appearance of psychotic symptoms
Day 10All drugs stopped till the resolutions of psychotic symptoms.Psychotic symptoms persisted
Day 11No ATT givenPsychotic symptoms resolved
Day 12Rifampicin 150 mgNo
Day 13Rifampicin 300 mgNo
Day 14Rifampicin 450 mgNo
Day 15Rifampicin 450 mg+ pyrazinamide 250mgNo
Day 16Rifampicin 450 mg+ pyrazinamide 500mgNo
Day 17Rifampicin 450 mg+ pyrazinamide 1500mgNo
Day 18Day 16 regimen + isoniazid 50 mgNo
Day 19Day 16 regimen + isoniazid 300 mg
Thus, isoniazid was also proved to be responsible for the causation of the psychotic symptoms and could not be reintroduced.Appearance of psychotic symptoms again
Day 20Day 16 regimenPsychotic symptoms persisted
Day 21Day 16 regimen continuedPsychotic symptoms resolved
The reintroduction schedule of antituberculous drugs in present case report Thus, both isoniazid and ethambutol proved to be responsible for his psychotic behavior and had to be stopped. He was, instead, prescribed rifampicin, pyrazinamide, and ofloxacin and had no further psychotic symptoms.

Discussion

Psychiatric disorders have traditionally been considered to be mental rather than physical illnesses. This is because they manifest with disordered functioning in the areas of emotions, perceptions, thinking, and memory, and/or have no established biological basis. Psychiatric disorders are diagnosed primarily by recognizing the pattern of symptoms. The term psychosis is used to described illness in which the patient has altered perception of reality as evidenced by delusions and or hallucination Our review of literature showed that most cases of antituberculous drug–associated psychoses were due to isoniazid; ethambutol-induced psychosis is rare and the concomitant occurrence in an individual of both isoniazid- and ethambutol-induced psychosis, as seen in the present case, is extremely rare. Isoniazid-related psychiatric disorders reported in the literature include psychosis, obsessive-compulsive neurosis, and mania.[1] Loss of memory and death following ingestion of isoniazid has also been reported.[2-3] The first description of psychotic symptoms due to isoniazid was by Mandel et al., who reported three such cases in 1956.[4] The mechanism of production of isoniazid-related psychiatric disorders is not clearly known, but isoniazid is known to interfere with several metabolic processes essential for the normal functioning of the neuron.[5] Isoniazid causes deficiency of vitamin B6 by causing excessive excretion of the vitamin, which in turn leads to a disturbance of normal tryptophan metabolism. Isoniazid also inhibits the activity of brain pyridoxal-5-phosphate (produced in the body from pyridoxine), which leads to a decrease in brain gamma-aminobutyric acid and other synaptic transmitters, resulting in neurologic ill effect.[6] Other predisposing factors for the occurrence of psychotic illness are diabetes mellitus, hepatic insufficiency, old age, alcoholism, and family and personal history of mental illness. Incidentally, no such risk factors were seen in our patient. There is great variability in the clinical features of isoniazid-induced psychosis in the various reported cases. Jackson, in 1957, reported five cases of isoniazid-induced psychosis that presented with excessive argumentation, mental depression, euphoria, grandiose ideas, and complex delusions; none of these patients had any previous history of mental illness.[7] Agarwala, in 1974, reported symptoms of restlessness, irritability, emotional instability, agitation, apprehension, and fluctuation in behavior after isoniazid therapy[8] (as was seen in our patient). Bedi, in 1994, reported a case of isoniazid psychosis in a 74-year-old, who developed restlessness, irritability, aimless activity, and incongruous actions 10 days after starting isoniazid therapy.[9] In 1996, Tiwari reported a case of isoniazid-induced psychosis with disturbed sleep, restlessness, and abnormal behavior[10] (as in the present case). The durations of psychotic symptoms in these case reports varied widely: i.e., 7–45 days,[7] 7 days,[8] 10 days,[9] and 120 days.[10] Ethambutol is one of the most commonly used drugs in the treatment of tuberculosis. The principle side effect is retrobulbar neuritis. Central nervous system toxicity is not widely reported and psychosis secondary to it is very rare.[11] The exact mechanism of ethambutol-induced psychosis is not clear. The symptomatology of ethambutol-induced psychosis is almost same as that of isoniazid. Hsu in 1999 reported a case of ethambutol-related psychosis where there were symptoms like dizziness, disorientation, and auditory and visual hallucinations after 7 days of ethambutol intake.[12] The diagnostic criteria for substance-induced psychosis, as per as DSM IV classification, are given below: Prominent hallucinations or delusions There is evidence from the history, physical examination, or laboratory findings of either (1) or (2): The symptoms in criterion A develop during, or within a month of, substance intoxication or withdrawal Medication use is etiologically related to the disturbance C. The symptoms precede the onset of the substance use (or medication use); the symptoms persist for a substantial period of time (e.g., about a month) after the cessation of acute withdrawal or severe intoxication, or are substantially in excess of what would be expected given the type or amount of the substance used or the duration of use; or there is other evidence that suggests the existence of an independent non-substance-induced psychotic disorder (e.g., a history of recurrent non-substance-related episodes). With regard to management, it is known that acute psychosis induced by isoniazid and ethambutol tends to subside once the precipitating stresses are over or their intensity is reduced. Thus, patients with isoniazid induced-psychosis recover without specific treatment after the withdrawal of the offending drug. The administration of pyridoxine, which has been advocated for the prevention and treatment of isoniazid-induced neurologic manifestations,[1] failed to achieve desired results in isoniazid-induced psychosis. In the present case, following discontinuation of all antituberculous agents, the psychiatric symptoms subsided. When the patient was challenged with isoniazid and ethambutol, the same psychiatric symptoms recurred, but resolved again after discontinuation of the drugs.

Conclusion

It is important to be aware that both isoniazid and ethambutol can induce psychosis concomitantly in an individual when antitubercular medications are prescribed.
  8 in total

Review 1.  PHARMACOLOGICAL ASPECTS OF VITAMIN B6.

Authors:  P HOLTZ; D PALM
Journal:  Pharmacol Rev       Date:  1964-06       Impact factor: 25.468

2.  Psychosis due to isoniazid.

Authors:  S L JACKSON
Journal:  Br Med J       Date:  1957-09-28

3.  Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.

Authors:  M L COHN; W MANDEL; G MIDDLEBROOK; W F RUSSELL
Journal:  Am J Med Sci       Date:  1957-01       Impact factor: 2.378

4.  Death following massive ingestion of isoniazid.

Authors:  S A Friedman
Journal:  Am Rev Respir Dis       Date:  1969-12

5.  Isoniazid and loss of memory.

Authors:  P Z Olsen; K Torning
Journal:  Scand J Respir Dis       Date:  1968

6.  Ethambutol-induced psychosis: a case report.

Authors:  C W Hsu; K A Chu; T Lu; R S Lai; J Y Lu
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1999-10

7.  Isoniazid-induced psychosis.

Authors:  A O Alao; J C Yolles
Journal:  Ann Pharmacother       Date:  1998-09       Impact factor: 3.154

8.  Ethambutol toxicity manifesting as acute onset psychosis.

Authors:  S J Martin; F J Bowden
Journal:  Int J STD AIDS       Date:  2007-04       Impact factor: 1.359

  8 in total
  10 in total

1.  An unusual case of isoniazid toxicity.

Authors:  Odysseas Kargiotis; Markos Marangos; Panagiotis Polychronopoulos
Journal:  Neurol Sci       Date:  2015-02-11       Impact factor: 3.307

Review 2.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

Review 3.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

4.  Pyrazinamide induced thrombocytopenia.

Authors:  Surya Kant; Sanjay Kumar Verma; Vaibhav Gupta; Sunish C Anand; Rajendra Prasad
Journal:  Indian J Pharmacol       Date:  2010-04       Impact factor: 1.200

5.  Cycloserine induced psychosis with hepatic dysfunction.

Authors:  Vishal R Tandon; Neelam Rani; Rahul Gupta; Manu Arora; Vijay Khajuria; Vivek Mahajan
Journal:  Indian J Pharmacol       Date:  2015 Mar-Apr       Impact factor: 1.200

6.  Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study.

Authors:  Tae Won Yang; Hyun Oh Park; Ha Nee Jang; Jun Ho Yang; Sung Hwan Kim; Seong Ho Moon; Joung Hun Byun; Chung Eun Lee; Jong Woo Kim; Dong Hun Kang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

7.  The possible impact of socioeconomic, income, and educational status on adverse effects of drug and their therapeutic episodes in patients targeted with a combination of tuberculosis interventions.

Authors:  Faisal Imam; Manju Sharma; Naif Obaid Al-Harbi; Mohammad Rashid Khan; Wajhul Qamar; Muzaffar Iqbal; Mohammad Daud Ali; Nemat Ali; Md Khalid Anwar
Journal:  Saudi J Biol Sci       Date:  2021-02-14       Impact factor: 4.219

8.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15

9.  Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N.

Authors:  Paolo Ascenzi; Andrea Coletta; Yu Cao; Viviana Trezza; Loris Leboffe; Gabriella Fanali; Mauro Fasano; Alessandra Pesce; Chiara Ciaccio; Stefano Marini; Massimo Coletta
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

10.  Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide.

Authors:  Bullo Saifullah; Alina Chrzastek; Arundhati Maitra; Bullo Naeemullah; Sharida Fakurazi; Sanjib Bhakta; Mohd Zobir Hussein
Journal:  Molecules       Date:  2017-10-12       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.